Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Twist Bioscience Corporation - Common Stock (NQ:TWST)

36.83 -1.62 (-4.22%)
Streaming Delayed Price Updated: 11:46 AM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Twist Bioscience Corporation - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Twist Bioscience to Expand Oregon Lease, Supporting Future Growth
From Twist Bioscience Corporation
Via Business Wire
Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Exercises Option to Purchase Custom Designed Antibody Library and Optimization Software
From Twist Bioscience
Via Business Wire
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
3 Exciting Biotech Stocks to Buy Right Now
Gene therapies could be poised to enter an era of extraordinarily rapid advancement. 
Via The Motley Fool
Twist Bioscience and Vivlion Partner to Generate gRNA Libraries for CRISPR Applications
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2021 Second Quarter Financial Results on Thursday, May 6, 2021
From Twist Bioscience Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2021
Upgrades For Eni SpA (NYSE:E), Credit Suisse upgraded the previous rating of Underperform to Neutral. For the fourth quarter, Eni had an EPS of $0.02, compared to year-ago... 
Via Benzinga
Ginkgo Bioworks, Which Prints DNA And Creates Genetically Modified Food, Exploring SPAC Deal: Report
One of the largest SPACs seeking a target could be nearing a $20 billion deal to bring one of the largest privately-held biotechnology companies public. The SPAC Rumor: Bloomberg... 
Via Benzinga
AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision Medicine Tests
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Provide Antibody Discovery, Optimization and Access to Library of Libraries for Drug Research to Stanford University Laboratories
From Twist Bioscience Corporation
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.